MCID: OVR010
MIFTS: 44

Ovarian Brenner Tumor

Categories: Cancer diseases, Reproductive diseases, Endocrine diseases

Aliases & Classifications for Ovarian Brenner Tumor

MalaCards integrated aliases for Ovarian Brenner Tumor:

Name: Ovarian Brenner Tumor 12 15
Brenner Tumor 44 73
Benign Ovarian Brenner Tumor 12
Benign Brenner Tumor 73

Classifications:



External Ids:

Disease Ontology 12 DOID:2636
MeSH 44 D001948
NCIt 50 C3872 C39954

Summaries for Ovarian Brenner Tumor

Disease Ontology : 12 An ovarian benign neoplasm that has material basis in the surface epithelium of the ovary.

MalaCards based summary : Ovarian Brenner Tumor, also known as brenner tumor, is related to transitional cell carcinoma and malignant ovarian brenner tumor. An important gene associated with Ovarian Brenner Tumor is UPK3A (Uroplakin 3A), and among its related pathways/superpathways are Cytoskeletal Signaling and Keratinization. The drugs Carboplatin and Paclitaxel have been mentioned in the context of this disorder. Affiliated tissues include ovary, brain and endothelial, and related phenotypes are embryo and renal/urinary system

Related Diseases for Ovarian Brenner Tumor

Diseases in the Ovarian Brenner Tumor family:

Malignant Ovarian Brenner Tumor

Diseases related to Ovarian Brenner Tumor via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 158)
# Related Disease Score Top Affiliating Genes
1 transitional cell carcinoma 30.7 KRT18 KRT20 KRT7 UPK3A
2 malignant ovarian brenner tumor 12.3
3 brenner tumor of ovary 11.2
4 renal pelvis transitional cell carcinoma 11.1 KRT7 UPK3A
5 cystic basal cell carcinoma 11.0 KRT20 KRT7
6 vaginal benign neoplasm 11.0 KRT20 KRT7
7 seminal vesicle adenocarcinoma 11.0 KRT20 KRT7
8 transverse colon cancer 11.0 KRT20 KRT7
9 appendix adenocarcinoma 11.0 KRT20 KRT7
10 ovarian large-cell neuroendocrine carcinoma 11.0 KRT20 KRT7
11 vaginal adenoma 11.0 KRT20 KRT7
12 vaginal tubulovillous adenoma 11.0 KRT20 KRT7
13 eyelid neoplasm 10.9 KRT20 KRT7
14 malignant syringoma 10.9 KRT20 KRT7
15 krukenberg carcinoma 10.9 KRT20 KRT7
16 large intestine adenocarcinoma 10.9 KRT20 KRT7
17 linitis plastica 10.9 KRT20 KRT7
18 malignant epithelial mesothelioma 10.9 THBD WT1
19 lung acinar adenocarcinoma 10.9 KRT20 KRT7
20 inverted transitional papilloma 10.9 GATA3 KRT7
21 small cell carcinoma of the bladder 10.9 KRT20 KRT7
22 adenoid squamous cell carcinoma 10.9 KRT20 KRT7
23 female reproductive endometrioid cancer 10.9 KRT7 WT1
24 eccrine sweat gland neoplasm 10.9 KRT20 KRT7
25 glandular cystitis 10.9 KRT20 KRT7 UPK3A
26 vulval paget's disease 10.9 KRT20 KRT7 UPK3A
27 proliferating trichilemmal cyst 10.9 KRT18 KRT7
28 renal pelvis adenocarcinoma 10.9 KRT7 PAX8
29 vulva adenocarcinoma 10.8 KRT20 KRT7 UPK3A
30 balloon cell malignant melanoma 10.8 KRT7 MME
31 ovarian benign neoplasm 10.8 KRT7 UPK3A
32 ovarian mucinous neoplasm 10.8 KRT20 KRT7 WT1
33 vulva cancer 10.8 KRT13 KRT7 UPK3A
34 transitional papilloma 10.8 KRT13 KRT18
35 inverted papilloma 10.8 KRT13 KRT20 KRT7
36 endosalpingiosis 10.8 KRT7 PAX8 WT1
37 cervical adenoma malignum 10.8 KRT7 MME
38 epithelial predominant wilms' tumor 10.7 KRT7 WT1
39 water-clear cell adenoma 10.7 GATA3 PAX8
40 ovarian cancer 1 10.7 KRT7 PAX8 WT1
41 malignant ovarian surface epithelial-stromal neoplasm 10.7 KRT7 PAX8 WT1
42 ovary epithelial cancer 10.7 KRT7 PAX8 WT1
43 cutaneous adenocystic carcinoma 10.7 KRT18 KRT7
44 papillary carcinoma 10.7 KRT20 KRT7 PAX8
45 lymphoepithelioma-like carcinoma 10.7 KRT18 KRT20 KRT7
46 metanephric adenoma 10.7 KRT18 KRT7 WT1
47 cervical mucinous adenocarcinoma 10.7 KRT7 MME
48 combined thymoma 10.7 PAX8 SALL4
49 endocervical carcinoma 10.6 KRT7 PAX8
50 mammary paget's disease 10.6 KRT18 KRT20 KRT7

Graphical network of the top 20 diseases related to Ovarian Brenner Tumor:



Diseases related to Ovarian Brenner Tumor

Symptoms & Phenotypes for Ovarian Brenner Tumor

MGI Mouse Phenotypes related to Ovarian Brenner Tumor:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 embryo MP:0005380 9.56 GATA3 KIT KRT18 PAX2 PAX8 SALL4
2 renal/urinary system MP:0005367 9.32 ANO1 GATA3 KIT KRT7 PAX2 PAX8

Drugs & Therapeutics for Ovarian Brenner Tumor

Drugs for Ovarian Brenner Tumor (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 88)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Carboplatin Approved Phase 3,Phase 2,Phase 1,Not Applicable 41575-94-4 10339178 498142 38904
2
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1 33069-62-4 36314
3
Bevacizumab Approved, Investigational Phase 3,Phase 1 216974-75-3
4
Cisplatin Approved Phase 3,Phase 2,Phase 1,Not Applicable 15663-27-1 84093 441203 2767
5
Docetaxel Approved, Investigational Phase 3,Phase 1,Phase 2 114977-28-5 148124
6
Gemcitabine Approved Phase 3,Phase 2 95058-81-4 60750
7
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
8
Mitoxantrone Approved, Investigational Phase 3 65271-80-9 4212
9
Glutamic Acid Approved, Nutraceutical Phase 3,Phase 1 56-86-0 33032
10 Albumin-Bound Paclitaxel Phase 3,Phase 2,Phase 1
11 Antimitotic Agents Phase 3,Phase 2,Phase 1
12 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
13 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
14 Angiogenesis Inhibitors Phase 3,Phase 1
15 Angiogenesis Modulating Agents Phase 3,Phase 1
16 Antibodies Phase 3,Phase 1
17 Antibodies, Monoclonal Phase 3,Phase 1
18 Endothelial Growth Factors Phase 3,Phase 1
19 Immunoglobulin G Phase 3,Phase 1
20 Immunoglobulins Phase 3,Phase 1
21 Mitogens Phase 3,Phase 1
22 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
23 Alkylating Agents Phase 3,Phase 1
24 Antineoplastic Agents, Alkylating Phase 3,Phase 1
25 Carotenoids Phase 3
26 Micronutrients Phase 3
27 Trace Elements Phase 3
28 Anti-Infective Agents Phase 3,Phase 2
29 Antimetabolites Phase 3,Phase 2
30 Antimetabolites, Antineoplastic Phase 3,Phase 2
31 Antiviral Agents Phase 3,Phase 2
32 taxane Phase 3
33 Analgesics Phase 3
34 Antirheumatic Agents Phase 3
35 Peripheral Nervous System Agents Phase 3,Not Applicable
36
Doxorubicin Approved, Investigational Phase 2,Phase 1 23214-92-8 31703
37
Belinostat Approved, Investigational Phase 2 866323-14-0
38
Iodine Approved, Investigational Phase 1, Phase 2 7553-56-2 807
39
Metformin Approved Phase 2 657-24-9 14219 4091
40
Xylometazoline Approved, Investigational Phase 2 526-36-3 5709
41
Doxil Approved June 1999 Phase 2,Phase 1 31703
42 Anti-Bacterial Agents Phase 2,Phase 1
43 Antibiotics, Antitubercular Phase 2,Phase 1
44 Histone Deacetylase Inhibitors Phase 2
45
Erlotinib Hydrochloride Phase 2,Phase 1 183319-69-9 176871
46 Protein Kinase Inhibitors Phase 2,Phase 1
47 Imatinib Mesylate Phase 2 220127-57-1 123596
48 Hypoglycemic Agents Phase 2
49
Bortezomib Approved, Investigational Phase 1 179324-69-7 387447 93860
50
Lenograstim Approved, Investigational Phase 1 135968-09-1

Interventional clinical trials:

(show all 48)
# Name Status NCT ID Phase Drugs
1 Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Completed NCT00262847 Phase 3 Carboplatin;Paclitaxel
2 Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Newly Diagnosed Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer Completed NCT00483782 Phase 3 carboplatin;paclitaxel
3 Paclitaxel and Cisplatin in Treating Patients With Stage III or Stage IV Ovarian Cancer or Primary Peritoneal Cancer Completed NCT00002717 Phase 3 cisplatin;paclitaxel
4 Combination Chemotherapy in Treating Patients With Primary Peritoneal or Stage III Epithelial Ovarian Cancer Completed NCT00003322 Phase 3 cisplatin;paclitaxel
5 Combination Chemotherapy With or Without Surgery in Treating Patients With Stage III Ovarian Epithelial Cancer Completed NCT00002568 Phase 3 cisplatin;paclitaxel
6 Carboplatin Plus Paclitaxel With or Without Continued Low-Dose Paclitaxel in Treating Patients With Early-Stage Ovarian Cancer Completed NCT00003644 Phase 3 carboplatin;paclitaxel
7 Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT00719303 Phase 3
8 Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Active, not recruiting NCT00951496 Phase 3 Carboplatin;Carboplatin;Cisplatin;Paclitaxel;Paclitaxel
9 Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer Active, not recruiting NCT01167712 Phase 3 Carboplatin;Paclitaxel
10 Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Active, not recruiting NCT00565851 Phase 3 Carboplatin;Docetaxel;Gemcitabine Hydrochloride;Paclitaxel
11 Paclitaxel, Polyglutamate Paclitaxel, or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Peritoneal Cancer, or Fallopian Tube Cancer Active, not recruiting NCT00108745 Phase 3 Paclitaxel;Paclitaxel Poliglumex
12 Chemotherapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Persistent Ovarian Epithelial Cancer Terminated NCT00002819 Phase 3 carboplatin;cyclophosphamide;mitoxantrone hydrochloride;paclitaxel
13 Acetyl-L-Carnitine Hydrochloride in Preventing Peripheral Neuropathy in Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer Undergoing Chemotherapy Withdrawn NCT01492920 Phase 3
14 VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer Unknown status NCT01666444 Phase 2 pegylated liposomal doxorubicin (PLD);VTX-2337;Placebo
15 Combination Chemotherapy Plus IM-862 in Treating Patients With Resected Stage III Ovarian Cancer or Primary Peritoneal Cancer Unknown status NCT00017303 Phase 2 carboplatin;oglufanide disodium;paclitaxel
16 A6 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Completed NCT00939809 Phase 2
17 Belinostat and Carboplatin in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Carboplatin or Cisplatin Completed NCT00993616 Phase 2 belinostat;carboplatin
18 Sargramostim and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Previous Chemotherapy Completed NCT00466960 Phase 2 paclitaxel albumin-stabilized nanoparticle formulation
19 Erlotinib Plus Carboplatin and Paclitaxel in Ovarian Carcinoma Completed NCT00059787 Phase 2 paclitaxel;carboplatin;erlotinib
20 Erlotinib, Docetaxel, and Carboplatin in Treating Patients With Newly Diagnosed Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer Completed NCT00217529 Phase 1, Phase 2 carboplatin;docetaxel;erlotinib hydrochloride
21 Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases Completed NCT00154388 Phase 2 Imatinib mesylate
22 MV-NIS Infected Mesenchymal Stem Cells in Treating Patients With Recurrent Ovarian Cancer Recruiting NCT02068794 Phase 1, Phase 2
23 Metformin and Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT02122185 Phase 2 metformin hydrochloride;placebo;Chemotherapy
24 Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Active, not recruiting NCT02101775 Phase 2 Adavosertib;Gemcitabine Hydrochloride
25 Elesclomol Sodium and Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Active, not recruiting NCT00888615 Phase 2 Elesclomol Sodium;Paclitaxel
26 Carboplatin, Paclitaxel, and Surgery in Treating Patients With Advanced Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer Terminated NCT00331422 Phase 2 carboplatin;paclitaxel
27 TLR8 Agonist VTX-2337 and Pegylated Liposomal Doxorubicin Hydrochloride or Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer Completed NCT01294293 Phase 1 TLR8 Agonist VTX-2337;Pegylated Liposomal Doxorubicin Hydrochloride;Paclitaxel
28 Intraperitoneal Bortezomib and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Completed NCT01074411 Phase 1 Bortezomib;Carboplatin
29 Polyglutamate Paclitaxel and Carboplatin in Treating Patients With Ovarian Epithelial, Peritoneal, or Fallopian Tube Cancer Completed NCT00060359 Phase 1 Carboplatin;Paclitaxel Poliglumex
30 Cisplatin and Paclitaxel in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer Completed NCT00814086 Phase 1 Paclitaxel;Cisplatin
31 Carboplatin and Paclitaxel With or Without Bevacizumab Compared to Docetaxel, Carboplatin, and Paclitaxel in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Carcinoma (Cancer) Completed NCT00085358 Phase 1 carboplatin;paclitaxel;docetaxel
32 Paclitaxel, Bevacizumab And Adjuvant Intraperitoneal Carboplatin in Treating Patients Who Had Initial Debulking Surgery for Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Completed NCT00079430 Phase 1 paclitaxel;carboplatin
33 Paclitaxel, Cisplatin, and Topotecan With or Without Filgrastim in Treating Patients With Newly Diagnosed Stage III or Stage IV Epithelial Ovarian Cancer Completed NCT00002913 Phase 1 paclitaxel;cisplatin;topotecan hydrochloride
34 Liposomal Doxorubicin and Carboplatin in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Completed NCT00006235 Phase 1 carboplatin;pegylated liposomal doxorubicin hydrochloride
35 Melphalan and Thiotepa Followed by Peripheral Stem Cell Transplantation in Treating Patients With Epithelial Ovarian Cancer in Complete Remission Completed NCT00002977 Phase 1 melphalan;thiotepa
36 Topotecan Plus Etoposide in Treating Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer Completed NCT00003967 Phase 1 etoposide;topotecan hydrochloride
37 Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial or Primary Peritoneal Cancer Completed NCT00005026 Phase 1 carboplatin;paclitaxel;topotecan hydrochloride
38 Immunotoxin Therapy in Treating Patients With Advanced Solid Tumors Completed NCT00066651 Phase 1
39 Immunotoxin Therapy in Treating Patients With Advanced Cancer Completed NCT00006981 Phase 1
40 Combination Chemotherapy in Treating Patients With Untreated Ovarian, Peritoneal, or Fallopian Tube Cancer Completed NCT00003385 Phase 1 carboplatin;paclitaxel;pegylated liposomal doxorubicin hydrochloride
41 Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer Active, not recruiting NCT00989651 Phase 1 Carboplatin;Cisplatin;Paclitaxel;Veliparib
42 Recombinant Measles Virus Vaccine Therapy and Oncolytic Virus Therapy in Treating Patients With Progressive, Recurrent, or Refractory Ovarian Epithelial Cancer or Primary Peritoneal Cancer Active, not recruiting NCT00408590 Phase 1
43 Liposomal Doxorubicin and Etoposide in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, or Peritoneal Cancer Terminated NCT00003380 Phase 1 etoposide;pegylated liposomal doxorubicin hydrochloride
44 Changes in Brain Function in Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Who Are Receiving Chemotherapy Completed NCT01080521
45 Collecting Tumor Samples From Patients With Gynecological Tumors Completed NCT00897442
46 Study of Previously Collected and Stored Tissue Samples From Patients Previously Enrolled in a Completed National Cancer Institute Clinical Trial Completed NCT00904514
47 Granisetron, Aprepitant, and Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Stage II, III, or IV Ovarian Cancer Terminated NCT01275664 Not Applicable Aprepitant;Carboplatin;Cisplatin;Dexamethasone;Granisetron Transdermal Patch
48 YKL-40 in Serum Samples From Patients With Newly Diagnosed Stage III-IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer Receiving Chemotherapy Terminated NCT00899093

Search NIH Clinical Center for Ovarian Brenner Tumor

Cochrane evidence based reviews: brenner tumor

Genetic Tests for Ovarian Brenner Tumor

Anatomical Context for Ovarian Brenner Tumor

MalaCards organs/tissues related to Ovarian Brenner Tumor:

41
Ovary, Brain, Endothelial, Cervix

Publications for Ovarian Brenner Tumor

Articles related to Ovarian Brenner Tumor:

(show all 16)
# Title Authors Year
1
Undiagnosed tubal high-grade serous carcinoma metastatic to synchronous benign ovarian Brenner tumor. ( 29567918 )
2018
2
Malignant ovarian Brenner tumor. A case report evaluated with (18)F-FDG PET/CT. ( 25890890 )
2015
3
Different staining patterns of ovarian Brenner tumor and the associated mucinous tumor. ( 25596159 )
2015
4
FDG PET/CT of a benign ovarian Brenner tumor. ( 22920385 )
2012
5
A borderline ovarian Brenner tumor mimicks uterine fibroids. ( 21482385 )
2011
6
Transitional cell carcinoma of the endometrium associated with benign ovarian brenner tumor: a case report with immunohistochemistry molecular analysis and a review of the literature. ( 17581415 )
2007
7
Left ovarian Brenner tumor. ( 16302335 )
2005
8
Leiomyomatosis peritonealis disseminata and ovarian Brenner tumor associated with tamoxifen use. ( 11520371 )
2001
9
Transitional cell carcinoma of the endometrium associated with a benign ovarian Brenner tumor: a case report. ( 11230712 )
2001
10
Immunohistochemical analysis of uroplakins, urothelial specific proteins, in ovarian Brenner tumors, normal tissues, and benign and neoplastic lesions of the female genital tract. ( 10514386 )
1999
11
Doppler ultrasound in a patient with ovarian Brenner tumor of low malignant potential: comparison with Gray-scale ultrasound, magnetic resonance imaging and tumor marker suggesting malignancy. ( 9067723 )
1997
12
Squamous cell carcinoma of the cervix metastatic to an ovarian Brenner tumor. ( 7617659 )
1995
13
A case of ovarian Brenner tumor with stromal estrogenic activity. ( 8092962 )
1994
14
The histologic features and histogenesis of malignant ovarian Brenner tumor. ( 3100186 )
1986
15
The coexistence of an ovarian Brenner tumor and endometrial stromal sarcoma. ( 4542422 )
1973
16
The ovarian Brenner tumor; its gross and microscopic pathology. ( 14789894 )
1950

Variations for Ovarian Brenner Tumor

Expression for Ovarian Brenner Tumor

Search GEO for disease gene expression data for Ovarian Brenner Tumor.

Pathways for Ovarian Brenner Tumor

Pathways related to Ovarian Brenner Tumor according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 12.16 KRT13 KRT18 KRT20 KRT7
2
Show member pathways
11.91 KRT13 KRT18 KRT20 KRT7
3
Show member pathways
11.53 KRT13 KRT18 KRT7
4 11 KIT MME THBD
5 10.67 MME PAX2 WT1
6 10.46 PAX2 PAX8

GO Terms for Ovarian Brenner Tumor

Cellular components related to Ovarian Brenner Tumor according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 keratin filament GO:0045095 9.13 KRT13 KRT18 KRT7
2 intermediate filament GO:0005882 8.92 KRT13 KRT18 KRT20 KRT7

Biological processes related to Ovarian Brenner Tumor according to GeneCards Suite gene sharing:

(show all 36)
# Name GO ID Score Top Affiliating Genes
1 keratinization GO:0031424 9.93 KRT13 KRT18 KRT20 KRT7
2 male gonad development GO:0008584 9.84 GATA3 KIT WT1
3 inner ear morphogenesis GO:0042472 9.81 GATA3 PAX2 PAX8
4 cornification GO:0070268 9.8 KRT13 KRT18 KRT20 KRT7
5 branching involved in ureteric bud morphogenesis GO:0001658 9.77 PAX2 PAX8 WT1
6 ventricular septum development GO:0003281 9.69 GATA3 PAX8 SALL4
7 cell fate determination GO:0001709 9.67 GATA3 PAX2
8 embryonic hemopoiesis GO:0035162 9.66 GATA3 KIT
9 negative regulation of programmed cell death GO:0043069 9.65 KIT PAX2
10 urogenital system development GO:0001655 9.65 PAX2 PAX8
11 cellular response to gonadotropin stimulus GO:0071371 9.65 PAX8 WT1
12 tissue development GO:0009888 9.65 GATA3 SALL4 WT1
13 metanephric mesenchyme development GO:0072075 9.64 PAX2 WT1
14 otic vesicle development GO:0071599 9.63 GATA3 PAX8
15 mesenchymal to epithelial transition involved in metanephros morphogenesis GO:0003337 9.62 PAX2 PAX8
16 pronephros development GO:0048793 9.62 PAX2 PAX8
17 regulation of metanephric nephron tubule epithelial cell differentiation GO:0072307 9.61 PAX2 PAX8
18 metanephric S-shaped body morphogenesis GO:0072284 9.61 PAX8 WT1
19 positive regulation of mesenchymal to epithelial transition involved in metanephros morphogenesis GO:0072108 9.59 PAX2 PAX8
20 metanephric nephron tubule formation GO:0072289 9.58 PAX2 PAX8
21 metanephric distal convoluted tubule development GO:0072221 9.58 PAX2 PAX8
22 ureter maturation GO:0035799 9.57 GATA3 PAX2
23 positive regulation of thyroid hormone generation GO:2000611 9.56 GATA3 PAX8
24 negative regulation of mesenchymal cell apoptotic process involved in metanephros development GO:1900212 9.55 PAX2 PAX8
25 nephric duct formation GO:0072179 9.54 GATA3 PAX2
26 mast cell differentiation GO:0060374 9.52 GATA3 KIT
27 pronephric field specification GO:0039003 9.46 PAX2 PAX8
28 positive regulation of metanephric DCT cell differentiation GO:2000594 9.43 PAX2 PAX8
29 mesonephros development GO:0001823 9.43 GATA3 PAX2 PAX8
30 negative regulation of mesenchymal cell apoptotic process involved in metanephric nephron morphogenesis GO:0072305 9.4 PAX2 PAX8
31 negative regulation of apoptotic process involved in metanephric collecting duct development GO:1900215 9.37 PAX2 PAX8
32 kidney development GO:0001822 9.35 GATA3 MME PAX8 UPK3A WT1
33 mesenchymal to epithelial transition GO:0060231 9.33 GATA3 PAX2 WT1
34 negative regulation of apoptotic process involved in metanephric nephron tubule development GO:1900218 9.32 PAX2 PAX8
35 metanephric epithelium development GO:0072207 8.8 PAX2 PAX8 WT1
36 transcription by RNA polymerase II GO:0006366 10.06 GATA3 PAX2 PAX8 SALL4 WT1

Molecular functions related to Ovarian Brenner Tumor according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.89 ANO1 GATA3 KIT KRT13 KRT18 KRT20
2 transcription regulatory region DNA binding GO:0044212 9.02 GATA3 PAX2 PAX8 SALL4 WT1

Sources for Ovarian Brenner Tumor

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....